An alternative classification defines three phenotypes: superficial peritoneal lesions (located less than 5 mm below the peritoneum), ovarian endometriomas, and deep infiltrating endometriosis (located more than 5 mm below the peritoneum)
has supported reclassifying peptides to improve peoples access to them
An advisory committee to the Food and Drug Administration voted yesterday to recommend that compounding pharmacies be allowed to make the peptide, even though it has little human-safety data and hasnt passed through the normal FDA drug-approval process
Discussions around TB-500 typically include careful assessment of patient history, physical demands, and tolerance for regenerative therapies, with ongoing monitoring when used under medical supervision
So by logical extension, if you're concerned about tumors or cancer of any kind, BPC-157 is probably not something that you want to explore